NCT01448759已完成不适用
Prospective Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel Infusion
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Evaluation of plasma alcohol
研究概览
简要总结
The purpose of this study is to evaluate plasma alcohol concentration in patients receiving Paclitaxel or Docetaxel infusion.
详细描述
In this study, there is no experimental treatment, or experimental care.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Chemotherapy with docetaxel or paclitaxel on an every 3-week schedule.
- •Patient with bitherapy are eligible only if the taxane is the first infusion.
- •All type of tumor.
- •Age>18 years old.
- •Signed written informed consent.
排除标准
- •Patient under
- •Patient with bitherapy, if docetaxel or paclitaxel is not administered first.
- •Patient deprived of liberty.
结局指标
主要结局
Evaluation of plasma alcohol
时间窗: One year
Measure of the plasma alcohol level before and after a taxane-based therapy (docetaxel or paclitaxel)
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
终止
2 期
Paclitaxel Detection in NSCLC Treated With TC RegimenNon-small Cell Lung CancerNCT02737709Sun Yat-sen University51
已完成
1 期
Paclitaxel Administered by HAI to Patients With Advanced Cancer and Dominant Liver InvolvementAdvanced CancerNCT00508326M.D. Anderson Cancer Center27
已完成
1 期
Drug-Eluting Balloon Catheters and the Treatment of Peripheral Arterial Occlusive DiseaseStenotic Femoro-popliteal ArteriesOccluded Femoro-popliteal ArteriesAtherosclerosisPeripheral Arterial DiseaseNCT01007578Bayer14
尚未招募
2 期
The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal CarcinomaNasopharyngeal CarcinomaNCT04769076The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School40
已完成
1 期
Phase I and Pharmacokinetic Trial of Paclitaxel (Taxol) Given as a 3-Hour Infusion in Pediatric Patients With Refractory MalignancyNeoplasmsNCT00001387National Cancer Institute (NCI)25